Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 4 1Phase 2/3 1

Status

Unknown 2Recruiting 2Completed 2

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Gastrointestinal 2Other hematologic neoplasm 1NET 1Lymphoid 1Gynecologic 1Endocrine 1Breast 1

Conditions

Serotonin Syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroendocrine Tumors 1Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Hepatocellular 1Carcinoid Tumors, Intestinal 1Carcinoid Tumor 1Breast Neoplasms 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Random Allocation × Clear all
NCT05361668 2026-03-19

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Crinetics Pharmaceuticals Inc.

Phase 2 Completed
36 enrolled 19 charts
EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT06860269 2026-02-10

GRAALL-2024

Assistance Publique - Hôpitaux de Paris

Phase 2/3 Recruiting
1,200 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06348719 2025-09-15

ROBOT-ECO-GYN

Rennes University Hospital

Phase NA Recruiting
1,680 enrolled
Gynecologic

Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma

NCT06550739 2024-08-13

Comprehensive Prognostic Model: The Study Introduces a Novel Prognostic Model That Incorporates a Wide Range of Clinical and Laboratory Variables, Providing a More Holistic Approach to Predicting Overall Survival in HCC Patients

Chongqing University Cancer Hospital

Completed
1,053 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT02812641 2019-03-11

Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC

National Taiwan University Hospital

Phase 2 Unknown
50 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT02590315 2019-01-31

ProteusDonna

Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Phase 4 Unknown
92,000 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡